{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:13:04Z","timestamp":1784826784217,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cllc.2025.08.014","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T05:35:51Z","timestamp":1756618551000},"page":"146-150.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Marta","family":"Brambilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barbetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Di Liberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Busico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1425-3354","authenticated-orcid":false,"given":"Daniele","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cllc.2025.08.014_bib0001","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","article-title":"Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer","volume":"12","author":"Castellanos","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.08.014_bib0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cllc.2025.08.014_bib0003","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.08.014_bib0004","article-title":"Molecular tumor Board as a clinical tool for converting molecular data into real-world patient care","volume":"7","author":"Vingiani","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.014_bib0005","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1038\/s41598-025-88494-3","article-title":"Detecting gene copy number alterations by Oncomine Comprehensive genomic profiling in a comparative study on FFPE tumor samples","volume":"15","author":"Bozzi","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.cllc.2025.08.014_bib0006","doi-asserted-by":"crossref","first-page":"662","DOI":"10.21037\/tlcr-20-814","article-title":"EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study","volume":"10","author":"Gieszer","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2025.08.014_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.644472","article-title":"The impact of variant allele frequency in EGFR mutated NSCLC patients on targeted therapy","volume":"11","author":"Friedlaender","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.014_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101865","article-title":"55P EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib","volume":"8","author":"Riva","year":"2023","journal-title":"ESMO Open"},{"issue":"21","key":"10.1016\/j.cllc.2025.08.014_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111694","article-title":"A prospective observational study on analyzing lung cancer gene mutation variant allele frequency (VAF) and its correlation with treatment efficacy","volume":"25","author":"Shinozaki","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cllc.2025.08.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100888","article-title":"Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors","volume":"38","author":"Bai","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.cllc.2025.08.014_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1498518","article-title":"First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis","volume":"14","author":"Zhang","year":"2025","journal-title":"Front Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425002219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425002219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:13:26Z","timestamp":1775042006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425002219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525730425002219"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.08.014","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}